Applied Therapeutics, Inc.: Nasdaq/NYSE listing notice — Applied Therapeutics receives Nasdaq deficiency notice for bid price below $1; cure period through Aug 6, 2025

Applied Therapeutics, Inc.

Nasdaq notified APLT on Feb 7, 2025 that closing bid price was below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until Aug 6, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by Aug 6, APLT may transfer to Nasdaq Capital Market for an additional 180-day grace period.
APLT is evaluating options but has not yet decided on a response; no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Applied Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 7, 2025, Applied Therapeutics, Inc. (the “ Company ”) received written notification (the “ Notice ”) from the Nasdaq Stock Market (“ Nasdaq ”) that, because the closing bid price for the Company’s common stock h

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Applied Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 7, 2025, Applied Therapeutics, Inc. (the “ Company ”) received written notification (the “ Notice ”) from the Nasdaq Stock Market (“ Nasdaq ”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(a)(1) (the “ Bid Price Requirement ”). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Market. Pursuant

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-25-017114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.